What are the recommended acute management guidelines for non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Guidelines for NSTEMI Management

For patients with NSTEMI, initiate dual antiplatelet therapy immediately with aspirin plus a P2Y12 inhibitor (preferably ticagrelor or prasugrel over clopidogrel), start anticoagulation, and stratify patients for invasive coronary angiography based on risk—immediate (<2 hours) for very high-risk features, early (<24 hours) for high-risk features including elevated troponin or GRACE score >140, and within 72 hours for intermediate-risk patients. 1, 2

Initial Diagnosis & Risk Stratification

Diagnostic Approach

• Use high-sensitivity cardiac troponin with a 0h/1h rapid protocol if available, or 0h/3h protocol 1
• If initial troponins are inconclusive but clinical suspicion remains high, repeat at 3-6 hours 1
• Obtain echocardiography to evaluate LV function and exclude differential diagnoses 1

Risk Stratification for Timing of Invasive Strategy

Very High-Risk (Immediate invasive strategy <2 hours): 1, 2

• Hemodynamic instability or cardiogenic shock
• Recurrent/ongoing chest pain refractory to medical treatment
• Life-threatening arrhythmias or cardiac arrest
• Mechanical complications of MI
• Acute heart failure with refractory angina or ST deviation
• Recurrent dynamic ST- or T-wave changes, particularly with intermittent ST elevation

High-Risk (Early invasive strategy <24 hours): 1, 2

• Rise or fall in cardiac troponin compatible with MI
• Dynamic ST- or T-wave changes (symptomatic or silent)
• GRACE score >140

Intermediate-Risk (Invasive strategy <72 hours): 1

• Diabetes mellitus
• Renal insufficiency (eGFR <60 mL/min/1.73 m²)
• LVEF <40% or congestive heart failure
• Early post-infarction angina
• Recent PCI or prior CABG
• GRACE score 109-140, or recurrent symptoms/known ischemia on non-invasive testing

Antiplatelet Therapy

Immediate Treatment (Before Angiography)

Aspirin: Administer immediately and continue indefinitely unless contraindicated 3, 4, 5, 6, 2

P2Y12 Inhibitor Selection: 1, 2

Ticagrelor is the preferred agent for moderate-to-high risk patients (e.g., elevated troponins):

• Loading dose: 180 mg
• Maintenance: 90 mg twice daily
• Can be given regardless of invasive vs. conservative strategy
• Use even if pretreated with clopidogrel (discontinue clopidogrel when starting ticagrelor)

Prasugrel for patients proceeding to PCI (P2Y12-naïve patients):

• Loading dose: 60 mg
• Maintenance: 10 mg daily (5 mg daily if age ≥75 years or weight <60 kg)
• Do NOT give prasugrel before coronary anatomy is known 1, 2
• Contraindicated: prior intracranial hemorrhage, prior ischemic stroke/TIA, ongoing bleeding

Clopidogrel (only when ticagrelor or prasugrel unavailable, not tolerated, or contraindicated):

• Loading dose: 300-600 mg
• Maintenance: 75 mg daily

Duration of Dual Antiplatelet Therapy

Continue DAPT for 12 months unless excessive bleeding risk 1, 5, 1, 2

Critical Pitfall

Do NOT routinely pre-treat with P2Y12 inhibitors in patients with unknown coronary anatomy planned for early invasive management 2. This represents a paradigm shift from older guidelines—wait until anatomy is defined unless using ticagrelor in high-risk patients.

Anticoagulation

Initial Anticoagulation (Choose One)

All patients require parenteral anticoagulation in addition to antiplatelet therapy 3, 4, 5, 2:

For patients proceeding to PCI:

• UFH: 70-100 IU/kg IV bolus (50-70 IU/kg if using GP IIb/IIIa inhibitor); target ACT 250-350 seconds (200-250 with GP IIb/IIIa) 3, 4, 2

For medical management or delayed transfer:

• Fondaparinux is preferred; give single UFH bolus at time of PCI 2
• Enoxaparin: Continue for duration of hospitalization, up to 8 days 3, 4, 5
• Bivalirudin: Discontinue 3 hours before CABG or continue at 0.25 mg/kg/hr up to 72 hours 3, 4

Duration

• Discontinue anticoagulation after uncomplicated PCI 3, 4, 5
• For medical management: Continue UFH for 48 hours or until discharge; enoxaparin/fondaparinux up to 8 days 3, 4, 5

Avoid Crossover

Do not switch between UFH and LMWH 2

GP IIb/IIIa Inhibitors

Current recommendation: NOT recommended routinely in patients with unknown coronary anatomy 2. This is a major change from older guidelines that recommended upstream GP IIb/IIIa therapy.

If used during PCI in high-risk troponin-positive patients, options include eptifibatide, tirofiban, or abciximab 3, 4.

Invasive Strategy Timing

The 2011 ACC/AHA update established that early invasive strategy (12-24 hours) is reasonable over delayed invasive strategy for initially stabilized high-risk patients 6, 5, 6. The 2015/2020 ESC guidelines further refined this with the three-tier risk stratification system described above.

Conservative Strategy Considerations

An initially conservative (selectively invasive) strategy may be considered for:

• Patients without high-risk features
• Extensive comorbidities where revascularization risks outweigh benefits
• Patient/physician preference in lower-risk patients 6, 5

However, proceed to angiography if: recurrent symptoms/ischemia, heart failure, or serious arrhythmias develop 6, 5, 6

Peri-Procedural Management for CABG

If CABG is planned and can be delayed:

• Discontinue clopidogrel 5-7 days before 3, 4
• Discontinue prasugrel or ticagrelor 7 days before 4
• Continue aspirin 3, 4
• Discontinue GP IIb/IIIa inhibitors 4 hours before 3, 4
• Discontinue enoxaparin 12-24 hours before; fondaparinux 24 hours before; bivalirudin 3 hours before—dose with UFH per institutional practice 3, 4

More urgent surgery may proceed if experienced surgeons deem incremental bleeding risk acceptable 3.

Secondary Prevention

Start high-intensity statin therapy immediately unless contraindicated, and maintain long-term 1

Special Populations

Patients Requiring Oral Anticoagulation

For atrial fibrillation with CHA₂DS₂-VASc ≥2 (males) or ≥3 (females) after stenting 2:

• Brief triple therapy (aspirin + clopidogrel + OAC) up to 1 week only
• Then dual therapy (clopidogrel + NOAC at stroke prevention dose) as default strategy
• Discontinue antiplatelet therapy after 12 months
• Do NOT use ticagrelor or prasugrel as part of triple therapy

Diabetes Mellitus

Medical treatment, stress testing, angiography, and revascularization decisions should be similar to non-diabetic patients 7. Maintain blood glucose <180 mg/dL while avoiding hypoglycemia 7.

Key Algorithmic Approach

1. Immediate: Aspirin + high-sensitivity troponin + ECG + risk stratification
2. Within 1 hour: Add P2Y12 inhibitor (ticagrelor preferred for high-risk) + anticoagulation
3. Timing to cath lab: <2h (very high-risk), <24h (high-risk including positive troponin/GRACE >140), <72h (intermediate-risk)
4. At PCI: Continue aspirin, ensure P2Y12 inhibitor loaded, use UFH
5. Post-PCI: DAPT for 12 months, high-intensity statin, discontinue anticoagulation if uncomplicated
6. If CABG needed: Hold P2Y12 inhibitors 5-7 days, continue aspirin

This evidence-based approach prioritizes the most recent ESC 2020 guidelines 2 and ACC/AHA 2012 focused update 4, 5, which supersede older recommendations while maintaining consistency with established principles.